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Neovascular age-related macular degeneration is one of the leading causes of blindness. 
Microglia and macrophages play critical role in choroidal neovascularization (CNV) and may 
therefore be potential targets to modulate the disease course. This study evaluated the effect of 
the colony stimulating factor-1 receptor (CSF-1R) inhibitor PLX5622 on experimental laser-
induced CNV. A 98% reduction of retinal microglia cells was observed in the retina one week 
after initiation of PLX5622 treatment, preventing accumulation of macrophages within the 
laser site and leading to a reduction of leukocytes within the choroid after CNV induction. 
Mice treated with PLX5622 had a significantly faster decrease of the CNV lesion size as 
revealed by in vivo imaging and immunohistochemistry from day 3 to day 14 compared to 
untreated mice. Several inflammatory modulators, such as CCL9, granulocyte-macrophage 
colony-stimulating factor, ssoluble tumor necrosis factor receptor-I, interleukin-1α, and 
matrix metallopeptidase-2 were elevated in the acute phase of the disease when microglia 
were ablated with PLX5622, whereas other cytokines (eg, interferon-γ, interleukin-4, and 
interleukin-10) were reduced. Our results suggest tha CSF-1R inhibition may be a novel 







The main feature of choroidal neovascularization (CNV) is new abnormal blood 
vessels emerging from the choroid and growing through Bruch’s membrane and sometimes 
the retinal pigment epithelium (RPE). CNV is observed during neovascular age-related 
macular degeneration (AMD) and can lead to vision loss in patients suffering from AMD.1, 2 
Although the particular pathogenesis of AMD remains u known, there are several previous 
studies showing the involvement of the innate immune system in the development of the 
disease 3-5.  
Microglia, residing in the retina, are dynamic surveillants of the extracellular 
environment,6 located mainly in the ganglion cell layer, the inner uclear layer, and the outer 
plexiform and nuclear layers. They can become reactive upon injury and acquire migration 
and proliferation capabilities.7 Several studies have suggested that along with resident 
microglia, infiltrating macrophages may also play a prominent role in the pathogenesis of 
AMD.8-11 In AMD, microglia/macrophages have been found in the sub-retinal space, where 
they are associated with drusen accumulation and CNV.12 In experimental laser-induced CNV 
microglia/macrophages depletion, using clodronate liposomes, resulted in reduced CNV size 
13, 14 and other studies have shown that the CNV area is significantly reduced in mice knocked 
out for the C-C chemokine receptor type 2 (CCR2), a crucial component mediating 
macrophage infiltration.15 CCR2 as well as the CX3C chemokine receptor 1 (CX3R1) are 
considered important factors for recruitment of macrophages to areas of inflammation and for 
the trafficking and the cellular migration of microglia into the sub-retinal space.12 There is 
increasing evidence for their role in AMD development as lower expression of CX3CR1 has 
been observed in patients with AMD.16 
The involvement of microglia/macrophages in CNV is further supported by studies 
showing that reduction of immune cells’ reactivity b  intravitreal injections of polysialic acid 
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leads to reduced vascular leakage in a laser-induced CNV mouse model.17, 18 Moreover, loss 
of interferon-β and transforming growth factor beta (TGF-β) signaling in retinal microglia has 
been implicated in increased microglia reactivity and exacerbated CNV lesions in mice, 19, 20 
supporting a role of microglia cytokine signaling in the course of CNV. 
Microglia depletion has been proven useful for the investigation of their involvement 
in several central nervous system (CNS) disease paradigms21, 22 and it has been recently 
shown that brain microglia can be effectively eliminated by colony stimulating factor-1 
receptor (CSF-1R) inhibition.23, 24 This was also observed in the retina, where microglia cells 
were eliminated by 92% to 97% in mice kept on a CSF-1R inhibitor–supplied diet for one 
week25, 26, while immune cells in the spleen were not affected after one to three weeks of 
PLX5622 treatment.27-29 However, PLX5622-dependent reduction of antigen presenting cells 
and Ly6Clow monocytes in the blood and the bone marrow have been r ported.29, 30 Cessation 
of CSF-1R inhibitor resulted in repopulation of retinal microglia from the remaining resident 
microglia pool in a CX3CR1 dependent manner.31, 32 However, more recent studies using 
bone marrow chimera mice suggest that monocyte-derived macrophages repopulate the retina, 
following cessation of PLX5622 treatment, where they adopt a ramified microglia-like 
morphology.33 Here, the CSF-1R inhibitor PLX5622 was used during the whole duration of 
the experiments to gain insight in the role of retinal microglia/macrophages on the course of 
experimental laser-induced CNV.  
 
Materials and Methods 
Animals 
This study was approved by the local Animal Ethics Committee (Veterinärdienst des 
Kantons Bern: BE 136/16) and conformed to the ARVO Statement for the Use of Animals in 
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Ophthalmic and Vision Research. Female mice were used, based on the observation that 
female mice are more prone to CNV formation.34 C57BL/6J mice (Charles River 
Laboratories, Sulzfeld, Germany) and MacGreen (B6N.Cg-Tg(Csf1r-EGFP)1Hume/J)35 
heterozygous female mice (6 to 8 weeks old) were employed.  
 Mice had ad libitum access to PLX5622-containing chow (1200 parts per million [ppm] 
formulated in AIN-76A standard rodent diet; Research Diets, Inc., New Brunswick, NJ) or 
AIN-76A standard rodent diet (control chow). Animals were housed, in groups of 2 to 5, 
under temperature and humidity-controlled conditions in individually ventilated cages with a 
12-hour light/12-hour dark cycle. Before laser treatment or imaging, mice were anesthetized 
with 1 mg/kg medetomidine (Dormitor 1 mg/mL; Provet AG, Lyssach, Switzerland) and 80 
mg/kg ketamine (Ketalar 50mg/mL; Parke-Davis, Zurich, Switzerland) as previously 
described.25 . At the end of the intervention, medetomidine was antagonized by injection of 
2.25 mg/kg atipamezol (Antisedan 5mg/mL; Provet AG). Before and one week after the 
initiation of the PLX5622 diet, as well as at days 3, 7, and 14 after laser treatment, mouse 
retinas were examined using confocal laser scanning ophthalmoscopy, fundus 
autofluorescence, and fluorescein angiography (Heidelberg Spectralis HRA 2; Heidelberg 
Engineering GmbH, Heidelberg, Germany). Groups of mice were euthanized with CO2 
inhalation at days 3 and 7 after laser treatment and their retinas and choroid-RPE complexes 
were prepared for fluorescence-based flow cytometry (FACS) or retina and choroid-RPE 
whole mounts and histology. All experiments were repeated at least once. 
 
Laser-induced Choroidal Neovascularization 
Mice were anesthetized and laser coagulation was performed using a 532-nm argon 
laser (Visulas 532s; Carl Zeiss Meditec AG, Oberkochen, Germany) with a slit-lamp adapter 
(Iridex Corporation, Mountain View, CA) mounted on a slit-lamp (BM900; Haag-Streit AG, 
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Koeniz, Switzerland). Pupil dilation was achieved with tropicamide 0.5%/phenylephrine 2.5% 
eyedrops (Hospital Pharmacy, Inselspital, Bern, Switzerland). Hydroxypropyl methylcellulose 
20 mg/mL (Methocel 2%; OmniVision AG, Neuhausen, Switzerland) was applied on the eyes 
to keep them hydrated. A 2-mm fundus lens (Ocular Instruments, Inc., Bellevue, WA) was 
used for fundus visualization during the laser application. Three spots per eye were applied 
around the optic nerve, avoiding the large vessels (50µm size, 300mW intensity, 100ms 
duration) and both eyes were lasered per mouse. Rupture of Bruch`s membrane was indicated 
by bubble formation directly after laser application. Lesions with obvious hemorrhage were 
excluded from analysis. Bridging between laser spots was avoided by positioning the laser 
sites with sufficient distance.  
 
Fundus Autofluorescence Imaging 
Mice were anesthetized and their pupils were dilated as described above. To avoid 
drying of the cornea with resulting impairment of image quality, hydroxypropyl 
methylcellulose 20 mg/mL (Methocel 2%; OmniVision AG, Neuhausen, Switzerland) was 
applied on each eye. Retinal images were acquired using an ultra-widefield 102º lens 
(Heidelberg Engineering GmbH, Heidelberg, Germany), as described previously.36 In 
MacGreen mice, GFP-positive cells (microglia/macrophages) could be visualized as 
hyperfluorescent spots in the autofluorescence images. 
 
Fluorescein Angiography 
After induction of anesthesia and pupil dilation (see above) 50 µL of 0.01% 
fluorescein [Faure; Novartis, Switzerland; in 1x phosphate buffered saline (PBS)] was 
administered subcutaneously and images were acquired sing the HRA system angiography 
(Heidelberg Spectralis HRA 2; Heidelberg Engineering GmbH, Heidelberg, Germany) with a 
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noncontact ultra-widefield 102º lens (Heidelberg Engineering GmbH, Heidelberg, Germany). 
Images were taken during the first 90 seconds. CNV area was marked and measured using the 
caliper function in the Heidelberg software by two blinded assessors (DK and PS) (Heidelberg 
Engineering GmbH, Heidelberg, Germany). 
 
Immunohistochemistry Studies 
For immunohistochemical studies, mouse eyes were isolated for preparation of retinal 
and choroid-RPE whole mounts. Eyes were fixed in 4% paraformaldehyde solution (PFA, pH 
7.4) for 10 minutes, the anterior segments were remov d (cornea and lens), and the posterior 
segment was incubated for another 50 minutes in PFA. Retinas were mechanically detached 
from the choroid-RPE complex and both tissues were ext nsively washed in 1x PBS, 0.5% 
TritonX-100 (Sigma-Aldrich, St. Louis, MO) and processed according to Ebneter, Kokona 37. 
Isolectin GS-IB4 from Griffonia simplicifolia (Alexa Fluor 647 conjugate; 1:100; Thermo 
Fisher Scientific, Waltham, MA), a rabbit polyclonal ntibody against ionized calcium-
binding adapter molecule 1 (Iba-1; 1:500; ; Wako Pure Chemical Industries Ltd., Osaka, 
Japan) and a chicken polyclonal antibody against GFP (1:300; Abcam, Cambridge, UK) were 
used for labeling of blood vessels and microglia/macrophages. The secondary antibodies goat 
anti-rabbit IgG H+L (Alexa Fluor 594 conjugate; 1:200; Thermo Fisher Scientific, Waltham, 
MA) was used for the visualization of Iba-1 staining and goat polyclonal antibody to chicken 
IgY H+L (FICH; 1:200; Abcam, Cambridge, UK) for visualization of GFP staining.  
Another group of mice was euthanized at days 3 or 7after CNV induction and their 
eyes were fixed in 4% PFA (pH 7.4) overnight at 4 °C. Eyes were routinely embedded in 
paraffin and 5 µm paraffin sections were cut running through the optic nerve head. The slides 
were de-paraffinized and blocked with 10% NGS for 30 min prior to incubation with a rabbit 
polyclonal antibody against Iba-1 (see above) overnight at 4 °C. The slides were washed in 1x 
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PBS and incubated with a secondary biotinylated goat anti-rabbit IgG antibody (1:250; Vector 
Laboratories, Burlingame, CA), for 30 min in room temperature, followed by three washes 
with 1x PBS and incubation with an HRP-streptavidin-co jugate (1:1000; Vector 
Laboratories, Burlingame, CA) for 60 min at room temperature. The signal was visualized 
using the NOVA red substrate kit (Vector Laboratories, Burlingame, CA) according to 
manufacturer’s instructions.     
 
Microscopy 
For retinal or choroid-RPE whole mounts, microscopy was performed on equipment 
provided by the Microscopy Imaging Center (MIC), University of Bern, Switzerland. Retinal 
and choroid-RPE flat mounts were examined using an inverted Zeiss LSM 710 fluorescence 
confocal microscope (Carl Zeiss Meditec AG, Jena, Germany). Z-stacks of 100 to 110 µm 
with 5 µm intervals were obtained. Eye sections were examined under a fluorescence Nikon 
Eclipse 80i microscope (Nikon, Tokyo, Japan). CorelD aw X6 (Corel Corporation, Ottawa, 
ON, Canada) was used for figure preparation. 
 
Flow cytometry 
Retinas and choroid-RPE complexes from MacGreen mice were used for flow 
cytometry analysis at days 3 and 7 after the laser pplication. The eyes were collected in PBS 
(pH 7.4), the anterior segment was removed, the retina was mechanically detached from the 
choroid-RPE complex and both tissues were used for flow cytometry. Retinas or choroid-RPE 
of each individual mouse were analyzed as one sample. Tissues were processed according to 
Ebneter, Kokona 37. Retinas were stained with fluorescent-labelled antibodies against CD45-
APC/Cy7 (30-F11, 1:400), CD11b-APC (M1/70, 1:200), and MHC-II-Pacific blue (major 
histocompatibility complex class-II, AF6-120.1, 1:200). Choroid-RPE samples were stained 
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with fluorescent-labelled antibodies against CD11b-APC (M1/70, 1:200), CD11c-APC/Cy7 
(N418, 1:200), Ly6G-PerCP/Cy5.5 (1A8, 1:200), Ly6C-Brilliant Violet 405 (HK1.4, 1:100), 
NK-1.1-PE/Dazzle 594 (PK146, 1:200), CD3-PE/Dazzle 594 (17A2, 1:200), and CD19-
PE/Dazzle 594 (6D5, 1:200). Zombie Red Fixable Viability Kit (1:800; Biolegend, San 
Diego, CA) staining was used for detection of dead cells, according to manufacturer’s 
instructions. Samples were incubated for 20 minutes with an Fc blocker (1:200; Biolegend, 
San Diego, CA) followed by incubation with the fluorescent-labelled antibodies for 20 more 
minutes at 4 °C in the dark. Each experiment was repeated at least once.  
An LSR II Cytometer System with the BD FACSDiva software V4.1 (BD 
Biosciences, Allschwil, Switzerland) was used for data acquisition. The flow cytometry data 
were analyzed with the Flowjo Single Cell Analysis Software V10 (TreeStar, Ashland, OR). 
All antibodies were purchased from Biolegend (San Diego, CA).  
 
Protein extraction  
In total, 34 C57BL/6J mice were used for protein extraction and analysis of cytokine 
and chemokine levels. Control or PLX5622-fed mice wre lasered as mentioned above one 
week after the initiation of the PLX5622 diet and proteins were extracted from the posterior 
part of the eyes at day 3 and 7 post CNV. Ten naïve mic  were used as naïve controls and four 
eyecups were pooled as one sample. Briefly, the eyecups were homogenized in 200 µL of 
lysis buffer [1x lysis buffer provided with the kit, 1 mM Na3VO4, protease inhibitor cocktail 
(cOmplete ULTRA Tablets, EDTA-free; Roche, Basel, CH)] and homogenized using a 
Precellys 24 tissue homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France). After 
centrifugation for 10 min at 13000 rpm at 4 °C, thesupernatant was collected and Bradford 




Mouse inflammation antibody array-membranes 
Mouse inflammation antibody array-membranes (ab193660; Abcam, Cambridge, UK) 
were processed according to manufacturer's instructions. Briefly, the membranes were 
incubated for 2 hours in blocking buffer (provided with the kit) and incubated with 500 µg of 
total protein, overnight at 4 °C. Membranes were washed (wash buffer provided with the kit) 
and incubated with biotin-conjugated anti-cytokines/chemokines (provided with the kit) in 
blocking buffer, overnight at 4 °C, and incubated with 1x HRP-conjugated streptavidin 
(provided with the kit), for 2 hours at room temperatu e. Chemiluminescence was detected 
using detection buffers (provided with the kit) and a Fusion Pulse Imaging System (Witec 
AG, Luzern, Switzerland). Densitometry analysis was performed using the “Protein Array 
Analyzer” function of the ImageJ2 software (https://imagej.net/ImageJ2; last accessed 
December 11, 2018).38 The signal was normalized between different membranes using the 
positive control spots. Spots with abnormally high background were excluded from the 
analysis. The experiment was repeated once.   
 
Statistical Analysis 
The sample size was estimated in the GPower 3.1 software39 based on a power of 0.8 
(80%) and a significance level of 0.05 (5%). The standardized difference (SMD) of each 
experimental group was estimated based on previous st dies and pilot experiments. 
D`Agostino-Pearson omnibus test or Kolmogorov-Smirnov test were used to test the normal 
distribution of different data sets. Repeated measures one-way ANOVA was used for the 
analysis of the CNV course with or without PLX5622 treatment. To compare the CNV area 
between PLX5622-treated and non-treated mice, ordina y one-way ANOVA was used 
followed by Tukey’s post hoc analysis. Statistically significant differences of the flow 
cytometry data were determined using one-way ANOVA followed by Tukey’s post hoc 
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analysis for normally distributed data and Kruskal-Wallis test followed by Dunn`s multiple 
comparison test for the data that did not follow normal distribution. Kruskal-Wallis test 
followed by Dunn`s multiple comparison test was used for the comparison of the array 
membrane data. All data are expressed as mean ± stadard deviation (SD). 
P-values less than 0.05 were considered statistically significant. GraphPad Prism 5.0 
software (GraphPad Software, Inc., San Diego, CA) was used for the statistical analysis.  
 
Results 
Effect of CSF-1R inhibition in the time course of laser-induced CNV  
Inhibition of the CSF-1R with PLX5622 for 7 days prior to CNV induction (Fig. 1A) 
led to a striking reduction of GFP positive cells in the retinas of mice (Fig. 1B). Laser 
application resulted in comparable CNV areas between PLX5622 treated and untreated mice 
three days after the CNV induction (Fig. 1C). However, the area of CNV was decreased at 
later time points in the CNV group (Fig. 1C), whereas the presence of PLX5622 resulted in an 
accelerated involution of CNV area over time (Fig. 1C). The leakage area of CNVs on the 
fluorescein angiographs substantiated this finding (Fi . 1D; *** P < 0.001, repeated measures 
one way ANOVA with Tukey’s post hoc analysis). Morev r, at day 14, there was a 
statistically significant decrease in CNV size of mice fed with PLX5622 compared to control-
fed mice (***P < 0.001, ordinary one way ANOVA with Tukey’s post hoc analysis).  
In the choroid-RPE complex, CNV areas were identified using isolectin GS-IB4 
staining (Fig. 2A). Iba-1 positive cells representing microglia/macrophages accumulated 
around the lesion sites in the choroid-RPE and retinal whole mounts of control mice (Fig. 
2A). In the PLX5622 group, Iba-1 positive cells, most probably representing macrophages, 
were present in CNV areas of the choroid-RPE but were absent from the neurosensory retina 
(Fig. 2A). In the choroid-RPE as well as in the outer retina, Iba-1 positive cells’ morphology 
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suggested a reactive phenotype, whereas in the inner retina most of the Iba-1 positive cells 
had a ramified morphology (Fig. 2B). Iba-1 positive cells were also detected in eye sections 
around the lasered area of CNV-subjected mice and their numbers were greatly reduced in the 
presence of PLX5622 (Fig. 2C). In the choroid-RPE complex of MacGreen CNV-subjected 
mice the majority of CSF-1R-GFP positive cells were co-localized with Iba-1, whereas a few 
cells (arrows) were Iba-1 negative (Fig. 2D).   
Quantification of microglia/macrophages with flow cytometry  
 Flow cytometry was performed at days 3 and 7 post CNV in the retina of control and 
PLX5622-treated CNV-subjected mice (Fig. 3A). The clls were gated as shown in 
Supplementary Figure 1A. CNV induced accumulation of CD45lowCD11b+ microglia and 
CD45hiCD11b+ macrophages40 in the retina, whereas PLX5622 reduced their numbers (Fig. 
3A). Quantification of different cell populations revealed that the number of microglia and 
macrophages was elevated 3 and 7 days post CNV (Fig. 3B; *** P < 0.001, ordinary one way 
ANOVA with Tukey’s post hoc analysis). In mice fed with PLX5622 microglia cells were 
diminished by approximately 98.5% compared to control CNV mice at day 3 and day 7 post 
CNV (Fig. 3B; ***P < 0.001, ordinary one way ANOVA with Tukey’s post hoc analysis). 
Similarly, PLX5622 led to a reduction of macrophages by 47.7% and 76.3%, respectively, 
compared to control at days 3 and 7 post CNV induction (Fig. 3B; ***P < 0.001, ordinary one 
way ANOVA with Tukey’s post hoc analysis). No statistically significant difference was 
observed in CSF-1R expression in different cell types for different treatments and time points 
(Fig. 3C). Increased MHC-II expression in both microglia and macrophages was observed at 
day 3 post CNV (Fig. 3C; ***P < 0.001, Kruskal-Wallis test followed by Dunn`s multiple 
comparison test). In mice fed with PLX5622 MHC-II expression in microglia and 
macrophages was virtually absent (Fig. 3C).  
Quantification of immune cell population in the choroid-RPE with flow cytometry  
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Flow cytometry was performed at days 3 and 7 post CNV in the choroid-RPE of control and 
PLX5622-treated mice. The cells were gated as shown in Supplementary Figure 1B. The 
number of CD11c+ cells, the majority of which most probably represent  dendritic cells41, 
leukocytes (CD11b+CD11cneg)42, and neutrophils (CD11b+Ly6G+)41 were elevated in the 
choroid-RPE during the acute phase of CNV (Fig. 4A;*P < 0.05, **P < 0,01, ***P < 0.001, 
ordinary one-way ANOVA with Tukey’s post hoc analysis for CD11c+ cells and leukocytes, 
Kruskal-Wallis test followed by Dunn`s multiple comparison test for neutrophils), whereas 
PLX5622 led to a reduction of CD11c+ ells and leukocyte numbers below control (naïve) 
levels (Fig. 4A). Interestingly, although there was no difference between the naïve and the 
CNV-subjected tissues in the total number of Ly6Gneg Ly6Clow/neg SSC-Hlow cells, representing 
non-classical patrolling monocytes/macrophages43, the presence of PLX5622 led to a 
reduction of these cell numbers below control (naïve) levels (Fig. 4B; ***P <  0.001, ordinary 
one way ANOVA with Tukey’s post hoc analysis). Classical inflammatory 
monocyte/macrophages (Ly6Gneg Ly6Chi)43 on the other hand, were increased at day 3 after 
CNV and this was prevented by PLX5622 (Fig. 4B; ***P <  0.001, ordinary one way 
ANOVA with Tukey’s post hoc analysis). The expression of CSF-1R by patrolling and 
inflammatory monocytes, expressed as a percentage of Ly6Gneg Ly6Clow/neg SSC-Hlow and 
Ly6Gneg Ly6Chi cells, respectively, was not altered between the diff rent groups (Fig. 4C, 
respectively).  
Cytokine levels during the course of CNV 
The protein levels of several inflammatory modulators such as chemokines (CCL3, 
CCL9), growth factors (IGFBP-3, IGFBP-5, GM-CSF), me bers of the TNF superfamily 
(CD30L, sTNFRI), inflammatory cytokines (interferon-γ, IFN-γ; interleukin-1α, IL-1α; 
inteleukin-12 p70, IL-12 p70), anti-inflammatory cytokines (interleukin-13, IL-13), matrix 
metalloproteinases (MMP-2, MMP-3), Fc gamma receptors (Fc-gamma RIIB), and adhesion 
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molecules (VCAM-1) were elevated at the acute phase of the disease (Table 1) 3 days after 
laser application. During the later phase (day 7), most of the inflammatory modulators 
returned to control levels except for an elevation of the protein levels of bFGF, GM-CSF, and 
VCAM-1. In the presence of PLX5622, protein levels of several targets were elevated (Table 
1), in agreement with previous studies,44 suggesting that PLX5622 actions are not mediated 
by a general reduction of the overall inflammatory response.  
 
Discussion 
Accumulation of microglia/macrophages in the subretinal space of CNV lesions and 
expression of inflammatory cytokines have both been implicated in the formation of CNV.10, 
12, 45, 46 However, the role of microglia/macrophages in CNV development is not clear yet, 
since contradictory roles of these cells have been r ported. Previous studies have shown that 
macrophage depletion can lead to a reduction of VEGF production and CNV lesion size in 
mice,13, 14 whereas other studies reported that lack of the CCR2 receptor and its ligand CCL2 
in mice leads to spontaneous CNV development after 9 months of age.2 Moreover, microglia 
accumulation has been observed in AMD lesions in CCL2/ X3CR1 deficient mice but not in 
control mice,47 whereas several additional studies reported that resident microglia actively 
contribute to CNV development.12, 48, 49 Microglia/macrophage involvement in CNV is further 
supported by studies showing that reduction of microglia and macrophages reactivity by 
polysialic acid or translocator protein 18 kDa (TSPO) ligands leads to reduced 
neurodegeneration and less vascular leakage in a CNV mouse model.17, 50, 51  
Here, we show that CSF-1R inhibition with PLX5622 leads to faster involution of 
CNV, as revealed by in vivo imaging and immunohistochemical studies in retinal and 
choroid-RPE whole mounts (Figure 1 and 2). PLX5622 efficiently depletes retinal microglia 
as early as one week of treatment (Figs. 1, 2, and 3). The flow cytometry data showed that 
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PLX5622 reduced the total number of CD45hiCD11b+ cells in the retina, most probably 
representing invading monocyte-derived macrophages and perivascular macrophages, and 
largely prevented MHC-II expression by microglia and CD45hiCD11b+ cells (Figure 3C). of 
the effect of PLX5622 was not observed on CSF-1R expression by microglia or macrophages 
(Fig. 3C). Recent studies by Paschalis et al suggested that ocular injury could trigger 
infiltration of peripheral monocytes into the retina, where they adopt a ramified morphology 
similar to resting microglia and express low levels of CSF-1R.33, 52 However, this was not 
observed in the present study. 
Flow cytometry analysis was also performed in the coroid-RPE complex of CNV 
subjected mice fed with control or PLX5622 chow. These data revealed increased numbers of 
CD11c+ cells, leukocytes, and neutrophils after CNV (Fig. 4), which is in agreement with 
previous studies.53, 54 CD11c+ dendritic cells have been previously reported to play a role in 
CNV development. Specifically, they have been found to accumulate in the CNV lesions, 
peaking in numbers between day 2 and 4 after laser-induced CNV in mice.54 Moreover, 
intravenous injection of dendritic cells leads to their accumulation into the CNV lesions where 
they are associated with increased CNV size.54 Our data are consistent with these findings. 
Moreover, inhibition of the CSF-1R with PLX5622 did not only deplete retinal microglia but 
it also affected the number of  CD11c+ ells and leukocytes found in the choroid-RPE by 
reducing their numbers below naïve levels, while it did not have any effect on neutrophil 
numbers (Fig. 4A). Previous studies have shown that CSF-1R signaling is vital for dendritic 
cells differentiation, and dendritic cells are diminished in the spleen and peritoneum of CSF-
1R deficient mice.55 Moreover, CSF-1R depletion has been recently shown to egatively 
regulate the dendritic cell pool size in adult mice.56   
Further analysis of leukocyte subsets showed an increase of inflammatory classical 
monocytes/macrophages (Ly6Gneg/Ly6Chi) 3 days post CNV, which was prevented by 
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PLX5622. However, the population of patrolling non-classical monocytes/macrophages in the 
choroid-RPE, identified as Ly6Gneg/Ly6Clow/neg/SSC-Hlow, was not affected by laser-induced 
CNV, but PLX5622 reduced their number below naïve leve s, while the remaining cells were 
still positive for CSF-1R expression (Fig. 4B). This suggests that PLX5622 leads to a 
reduction of resident choroidal macrophage numbers and prevents the recruitment of Ly6Chi 
inflammatory monocytes/macrophages into the affected area. Indeed, by using neutralizing 
antibodies against CSF-1R or its ligand CSF-1, it has been previously shown that blocking of 
CSF-1R signaling can lead to depletion of Ly6Cneg monocytes in the blood, while it only has 
modest effects in Ly6C+ monocytes in the bone marrow.57-59 Thus, the beneficial effects of 
PLX5622 may be attributed at least partially to thereduced numbers of peripheral immune 
cells, which along with retinal microglia could contribute to the extracellular matrix 
remodeling that trigger the formation of new blood vessels. 
To further investigate the effect of PLX5622 in the course of CNV, a panel of 
cytokines/chemokines were analyzed in CNV-subjected mice fed with PLX5622 or normal 
food, using a semi-quantitative assay (the array membrane data are openly available in 
OSF|Data repository - Open Science Framework at https://osf.io; reference number: y5n7h). 
Elevated levels of several cytokines/chemokines were found in the CNV-subjected eyes, 
while some of them were elevated even more in the presence of PLX5622 (Table 1). Among 
the highest up-regulated cytokines were CX3CL1, MMP-2, bFGF, and VCAM-1, whereas 
others, such as IL-6, TNFα, and MCP-1 were not changed compared to naïve mice. CX3CL1 
signaling is a key modulator of macrophage recruitment into the injured tissues60, 61 and it has 
been shown to reduce microglial activation and subsequent neurotoxicity.62, 63 MMP-2 on the 
other hand has been reported to play a prominent role in CNV formation, since reduced CNV 
is observed in mice deficient for MMP-2.64-66 MMPs can proteolytically cleave several 
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chemokines, leading to their inactivation or the generation of antagonistic derivatives, which 
cannot promote chemotaxis.67  
No differences were detected in the levels of vascul r endothelial growth factor 
(VEGF) between the experimental groups 3 and 7 days after CNV induction. VEGF is 
considered the major pro-angiogenic factor in the inflamed retina,68-70 and it has been 
suggested that interaction between VEGF and other pro-angiogenic factors, such as bFGF, is 
required for the angiogenic actions of VEGF.71 Here, an up-regulation of bFGF was observed 
in the presence or absence of PLX5622, but no differences were observed in VEGF protein 
levels between naïve and CNV mice in the presence or absence of PLX5622. Most likely, 
these differences could be observed in earlier timepoints after the CNV induction.  
In the presence of PLX5622, the pro-inflammatory IL-1α was also elevated at day 3 
after CNV laser-induction and it was significantly reduced at day 7. Up-regulation of the 
adhesion molecule VCAM-1 was also observed in our st dy and this up-regulation was 
greater in the presence of PLX5622. VCAM-1 mediates the adhesion of monocyte-derived 
macrophages to vascular endothelial cells and increased protein levels of VCAM-1 have been 
reported in the retinal vasculature during CNV in mice.11 However, increased infiltration of 
monocyte-derived macrophages into the injured retina was not observed in the presence of 
PLX5622.  
Additionally, significantly elevated levels of sTNFRI were found during the disease 
course of CNV in the presence of PLX5622. After TNF-α binds to its membrane receptors, 
TNFRI and TNFRII, the receptors are cleaved to their soluble forms (sTNFRI/sTNFRII) by 
metalloproteinases.72 The level of surface expression of TNFRI and its soluble form was 
found to be an important factor in regulating TNFα-mediated effects,73, 74 and the receptor 
cleavage acts as an important mechanism for the suppression of TNF-α–mediated 
inflammation.75 The levels of the anti-inflammatory cytokines IL-4 and IL-10 were also 
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elevated in the PLX5622 group, and this was accompanied by down-regulation of IFN-γ 
levels. Indeed, IL-10 has been previously reported to inhibit the production of IFN-γ76 and to 
mediate a suppressive effect on CNV development.77 In addition, IL-4 has been shown to 
antagonize IFN-γ–induced activities in macrophages.78-80 The expression of insulin-like 
growth factor–binding proteins (IGFBP-3, IGFBP-5, and IGFBP-6) was also increased in the 
presence of PLX5622. IGFBPs bind with high activity to insulin growth factor (IGF) and thus 
limit the free form of IGF in the circulation, 84-86 thereby acting as angiogenesis 
suppressors.87-89 In keeping with this IGF signaling has been proposed to play a role in 
diabetic retinopathy and retinal neovascularization where it has been shown to lead to 
increased VEGF levels.81-83  
Because of complex cytokine interactions that may act antagonistically, the apparent 
increase of the inflammatory cytokines after PLX5622, which is in keeping with previously 
published studies44, may ultimately lead to a more angiostatic/anti-angiogenic phenotype and 
thus inhibits CNV progression. In addition, it has been previously reported that CSF-1 can 
increase the release of VEGF from monocytes and CSF-1R inhibition can lead to lower levels 
of VEGF.90, 91 Thus, blockade of the receptor may affect the angiogenesis mediated by CSF-
1R–expressing cells. Moreover, physical contact betwe n immune cells, such as perivascular 
macrophages, and endothelial cells may be required for the progression of CNV. In vitro 
studies have shown that direct contact between monocytes and endothelial cells can increase 
endothelial cell proliferation.92 49, 93 Hence, reduction of retinal microglia and attenuation of 
perivascular macrophages could result in decreased endothelial cell proliferation and therefore 
regression of CNV lesions.  
Our data are in agreement with previous studies that have shown elevation of cytokine 
and chemokine levels in the retinas of CNV-subjected mice, as well as infiltration of 
monocyte-derived macrophages into the retina early during the course of CNV.11, 94-96 Apart 
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from microglia and monocyte-derived macrophages, RPE cells and vascular endothelial cells 
are also known to produce cytokines during CNV in mce.97 Moreover, activated Müller cells 
could also be a source of cytokines during CNV. Based on the PLX5622 depletion data, 
immune cells are likely not the main producers of cytokines during the course of our CNV 
model, yet they play an important role in CNV progression.  
In summary, the present study highlights the important role of innate immunity in the 
course of CNV in mice. Inhibition of the CSF-1R has beneficial effects against CNV 
progression but whether these effects are mediated by depletion of microglia and/or 
macrophages in the retina, by patrolling monocytes in the choroid or by the prevention of 
leukocyte influx needs to be further investigated. A ditionally, a more detailed analysis of the 
cytokine and chemokine levels after PLX5622 treatment could provide valuable data towards 
specific biological effects of PLX5622 in retinal pathology.  
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Figure 1. Effect of colony stimulating factor-1 receptor (CSF-1R) inhibition on choroidal 
neovascularization. A: Experimental setup. B: Representative autofluorescence images of a 
MacGreen mouse retina before (PLX5622 d-7, n = 3 mice) and 7 days after the start of 
PLX5622 diet (PLX5622 d0, n = 3). GFP positive microglia cells are drastically diminished in 
the retina after 7 days of PLX5622 diet. C: Representative fluorescein angiographs of 
choroidal neovascularization (CNV)-subjected eyes at different time points in control or 
PLX5622-fed mice. D: CNV area measurements in fluorescein angiographs of control or 
PLX5622-fed mice. CNV area was gradually decreased in control (CNV) and PLX5622-fed 
mice. ***P < 0.001, repeated measures one way ANOVA followed by Tukey’s post hoc 
analysis; n ≥ 14 eyes per group. Statistically significant reduction of the lesion size was 
observed in the presence of PLX5622 at day 14 compared to the control. ***P < 0.001, 
ordinary one way ANOVA followed by Tukey’s post hoc analysis; n ≥ 14 eyes per group. 
Individual CNV lesions are plotted in the graph.    
 
Figure 2. Ex vivo evaluation of microglia and accumulation of monocyte-derived 
macrophages in the laser site. A: Isolectin and Iba-1 staining in the choroid-RPE whole 
mounts and Iba-1 staining in retinal whole mounts 14 days post choroidal neovascularization 
(CNV) in control (n ≥ 6 mice per group) and PLX5622-fed mice. Iba-1–positive cells 
accumulate at the laser site in the choroid-RPE and in the retina of control CNV-subjected 
mice. In PLX5622-fed mice Iba-1–positive cells are detected in the choroid-RPE but not in 
the retinal whole mounts. The numbers indicate the thr e different laser spots and the asterisks 
indicate the optic nerve head. Scale bars: 500 µm; magnification: 10x B: Higher 
magnification of Iba-1 staining in control-fed mice subjected to CNV, 14 days after the laser 
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application. In the choroid-RPE and the outer retina, Iba-1–positive cells accumulated around 
the laser site and their morphology is characterized by increased soma size and retracted 
processes. In the inner retina a ramified morphology is observed. Scale bars: 200 µm; 
magnification: 40x. C: Representative photomicrographs of Iba-1–positive cells in retinal 
sections of control (n ≥ 3 mice per time point) or PLX5622-fed (n ≥ 3 mice per time point) 
CNV-subjected mice. Iba-1–positive cells accumulated in the outer retinal and the choroid-
RPE in the CNV eyes (first and second panel). In mice fed with PLX5622, Iba-1–positive 
cells also accumulated in the outer retina and choroid-RPE; however, they were fewer in 
number and were almost absent 7 days after CNV (third and fourth panel). IPL, inner 
plexiform layer; ONL, outer nuclear layer. Scale bars: 200 µm; magnification: 20x. D: 
Representative photomicrographs of Iba-1 and CSF-1R-GFP positive cells in retinal sections 
of control or PLX5622-fed mice 14 days after CNV (n ≥ 3 mice per treatment). Most of the 
CSF-1R-GFP positive cells are co-localized with Iba-1 while a few of them are Iba-1 negative 
(arrows). Scale bars: 100 µm; magnification: 40x.  
 
Figure 3. Flow cytometry analysis of microglia/macrophages population in the retina of 
choroidal neovascularization (CNV)-subjected mice. A: Representative flow cytometry plots 
at different time points post CNV in control and PLX5622-fed animals. Microglia were 
identified as CD45low CD11b+ and macrophages as CD45hi CD11b+. B: Quantification of 
microglia (upper panel; CD45low CD11b+) and macrophages (lower panel; CD45hi CD11b+) in 
the retina, 3 and 7 days post CNV, in the presence or absence of PLX5622. Elevated number 
of microglia and macrophages is observed 3 and 7 days post CNV (n ≥ 5 mice per group). 
PLX5622 reduces the number of microglia and macrophages in the retina (n ≥ 5 mice per 
group). C: Quantification of CSF-1R+ or MHC-II+ microglia (first and second graph) and 
CSF-1R+ or MHC-II+ macrophages (third and fourth graph), expressed as a percentage of the 
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total number of microglia or macrophages, respectivly. No statistically significant difference 
was observed in the number of CSF-1R+ microglia and macrophages in the presence or 
absence of PLX5622. MHC-II+ microglia and macrophages were detected in the retina at the 
early course of CNV (day 3), yet this increase was not statistically significant compared to the 
naïve tissue. PLX5622 reduces the expression of MHC-II by these cells ***P < 0.001, one-
way ANOVA followed by Tukey’s post hoc analysis or K uskal-Wallis test followed by 
Dunn`s multiple comparison test, n ≥ 5 per group).  
 
Figure 4. Quantification of immune cell population in the choroid-RPE using flow cytometry 
analysis. A: The numbers of CD11c+ cells (first graph) in the choroid-RPE is elevated 3 ays 
after choroidal neovascularization (CNV) and returns to control levels at day 7 post CNV. 
PLX5622 reduces CD11c+ cell numbers below control levels. Leukocyte numbers (second 
graph) peak at day 3 after CNV and their numbers are reduced in the presence of PLX5622. A 
slight increase in neutrophil numbers is detected 3 days post CNV (third graph). B: 
Leukocytes were further gated based on the expression of Ly6G and Ly6C. Ly6Gneg 
Ly6Clow/neg SSC-Hlow cells are reduced in the presence of PLX5622 while no differences are 
observed between the naïve and CNV subjected tissues (first graph). On the other hand, 
Ly6Gneg Ly6Chi inflammatory monocytes/macrophages are increased 3 days post CNV and 
decreased thereafter (second graph) and this phenomenon is prevented by PLX5622. C: No 
difference is observed in the expression of colony stimulating factor-1 receptor (CSF-1R) by 
Ly6Gneg Ly6Clow/neg SSC-Hlow (first graph) or Ly6Gneg Ly6Chi monocytes/macrophages 
(second graph) between different treatments. *P < 0.05, **P < 0.01, ***P < 0.001, ordinary 
one way ANOVA with Tukey’s post hoc analysis or Kruskal-Wallis test followed by Dunn`s 





Table 1. Effect of laser-induced CNV on cytokine/chemokine levels in the C57BL/6J 
mouse eyecups in the presence or absence of PLX5622. 
 Day 3 Day 7 
Factors CNV CNV+PLX5622 CNV CNV+PLX5622 
Chemokines     
CCL3 1.60* 1.11 0.85‡‡ 0.55 
CCL9 1.58***  2.36***†††  1.26 2.62***†††  
CX3CL1 1.34 4.59***  1.39 3.75***  
CXCL2 1.19 1.46***  1.08 1.39**†  
CXCL13 1.34 2.12***†  1.06 1.46 
CXCL16 1.29 2.38***†††  1.11 2.45***†††  
     
Growth factors     
bFGF 1.67 2.06* 2.12***  3.00***†  
IGFBP-3 1.33**  1.83***†††  1.08 1.70***†††  
IGFBP-5 1.45* 2.41***†††  1.12 1.92***†††  
IGFBP-6 1.13 2.80**†  1.32 1.84 
GM-CSF 1.68* 2.89***†††  1.66* 1.91**‡‡ 
M-CSF 1.12 1.33* 1.15 1.02 
     
TNF superfamily     
CD30 1.21 2.03**†  1.09 1.54 
CD30 L 1.43* 1.40 1.09 0.92 
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Fas ligand 0.79 1.75†† 0.85 0.93 
sTNFRI 1.53* 2.58***†††  0.86‡‡ 2.35***†††  
     
Pro-Inflammatory cytokines    
IFN-g 1.70* 0.54††† 1.14‡ 0.46† 
IL-1α 1.34* 2.31***†††  1.12 1.60***††‡‡‡ 
IL-12 p70 1.48**  1.76***  1.09‡ 1.50* 
TCA-3 1.20 1.86***†††  0.95 1.73***†††  
TIMP-1α 1.23 1.59**  0.93 1.41† 
     
Anti-inflammatory cytokines    
IL-4 1.06 2.72††† 0.89 2.75††† 
IL-10 1.40 3.13***†††  1.53 2.00*‡ 
IL-13 1.45**  1.35 1.08† 0.84‡ 
     
Tissue remodeling     
MMP-2 1.86***  5.07***†††  0.84‡ 5.62***†††  
MMP-3 1.59* 1.85**  1.13 2.29***†††  
     
Fc-gamma receptors    
Fc gamma RIIB 2.19**  0.43†† 1.45 0.89 
     
Adhesion molecules    




Semi-quantitative analysis of inflammatory mediators’ protein levels in the retina-choroid-
RPE complex, 3 and 7 days after CNV, in the presence or absence of PLX5622. All data are 
normalized to naive tissues.  
*P < 0.05, ** P < 0.01, *** P < 0.001 compared to naïve. 
†P < 0.05, ††P < 0.01, †††P < 0.001 compared to CNV. 
‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 compared to the same treatment at day 3.  
Only targets with statistically significant differences are shown in the table. Targets that were 
examined but did not show statistically significant differences included IL-6, TNFα, VEGF, 
MCP-1, G-CSF, and CCL5 among others.  
 




